Renan A Bonnel

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi Aseptic meningitis associated with rofecoxib
    Renan A Bonnel
    Office of Postmarketing Drug Risk Assessment, Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Ln, Room 15B 23, HFD 430, Rockville, MD 20857, USA
    Arch Intern Med 162:713-5. 2002
  2. ncbi Peripheral neuropathy in patients treated with leflunomide
    Renan A Bonnel
    Office of Drug Safety, Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, MD 20857, USA
    Clin Pharmacol Ther 75:580-5. 2004
  3. ncbi Deaths associated with inappropriate intravenous colchicine administration
    Renan A Bonnel
    Office of Drug Safety, Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, Maryland 20857, USA
    J Emerg Med 22:385-7. 2002
  4. ncbi Allergic contact dermatitis from topical doxepin: Food and Drug Administration's postmarketing surveillance experience
    Renan A Bonnel
    Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Room 15B-23, HFD-430, Rockville, MD 20857, USA
    J Am Acad Dermatol 48:294-6. 2003
  5. ncbi Abuse, dependence, or withdrawal associated with tramadol
    Allen Brinker
    Am J Psychiatry 159:881; author reply 881-2. 2002
  6. ncbi Re: Postmarking adverse events related to sotradecol (sodium tetradecyl sulfate-sclerosing agent)
    Renan A Bonnel
    Am J Gastroenterol 97:2140; author reply 2140. 2002

Detail Information

Publications6

  1. ncbi Aseptic meningitis associated with rofecoxib
    Renan A Bonnel
    Office of Postmarketing Drug Risk Assessment, Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Ln, Room 15B 23, HFD 430, Rockville, MD 20857, USA
    Arch Intern Med 162:713-5. 2002
    ..To our knowledge, there have been no published reports of aseptic meningitis occurring in association with rofecoxib use to date. We report 5 serious cases of aseptic meningitis associated with rofecoxib use...
  2. ncbi Peripheral neuropathy in patients treated with leflunomide
    Renan A Bonnel
    Office of Drug Safety, Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, MD 20857, USA
    Clin Pharmacol Ther 75:580-5. 2004
    ..Our objective was to describe the clinical features, time course, and outcome of new-onset peripheral neuropathy occurring in patients treated with leflunomide...
  3. ncbi Deaths associated with inappropriate intravenous colchicine administration
    Renan A Bonnel
    Office of Drug Safety, Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, Maryland 20857, USA
    J Emerg Med 22:385-7. 2002
    ..Death occurred within 1 to 40 days after drug administration. Therapeutic guidelines exist for use of IV colchicine and these guidelines should be followed to prevent serious toxicities and death...
  4. ncbi Allergic contact dermatitis from topical doxepin: Food and Drug Administration's postmarketing surveillance experience
    Renan A Bonnel
    Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Room 15B-23, HFD-430, Rockville, MD 20857, USA
    J Am Acad Dermatol 48:294-6. 2003
    ..Allergic contact dermatitis to doxepin cream should be considered in patients whose condition fails to improve or worsens with doxepin use...
  5. ncbi Abuse, dependence, or withdrawal associated with tramadol
    Allen Brinker
    Am J Psychiatry 159:881; author reply 881-2. 2002
  6. ncbi Re: Postmarking adverse events related to sotradecol (sodium tetradecyl sulfate-sclerosing agent)
    Renan A Bonnel
    Am J Gastroenterol 97:2140; author reply 2140. 2002